A Clinical Study of Intratumoral MVR-C5252 (C5252) in Patients With Recurrent or Progressive Glioblastoma

Solid Tumor Clinical Trial

Official title:

A Phase 1 Open-Label Study of Genetically Engineered Oncolytic HSV-1 (C5252) Expressing IL-12 and Anti-PD-1 Antibody in Patients With Recurrent or Progressive Glioblastoma

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05095441
• Other study ID #: MVR-C5252-001
• Status: Not yet recruiting
• Phase: Phase 1
• Start date: March 15, 2023
• Est. completion date: April 30, 2026

Study information

• Verified date: October 2022
• Source: ImmVira Pharma Co. Ltd
• Contact: ImmVira Pharma Co., LTD
• Phone: 781-718-5121
• Email: clinicaltrials[@]immviragroup.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase 1 open label, first in human study of C5252 monotherapy designed to determine the safety and tolerability of a single intratumoral (IT) injection of C5252 in patients with recurrent or progressive glioblastoma (GBM).

Description:

This is a Phase 1 open label, first in human study of C5252 monotherapy designed to determine the safety and tolerability of a single IT injection of C5252 in patients with recurrent or progressive GBM. The Part 1 portion of the study is a 3+3 design to evaluate escalating doses of C5252. Total enrollment will depend on the toxicities and/or activity observed, with approximately 36 evaluable participants enrolled. Once the recommended dose (RD) is identified from Part 1, Part 2 Dose Expansion will enroll up to 15 additional participants to further assess the safety, tolerability, and preliminary efficacy of a single IT injection of C5252 monotherapy.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 51
• Est. completion date: April 30, 2026
• Est. primary completion date: April 30, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Key Inclusion Criteria:

1. Signed and dated approved informed consent form (ICF) before any protocol-directed screening procedures are performed.

2. Participants must have histopathologically confirmed recurrent supratentorial glioblastoma.

3. Participants must have progressed after at least 1 line but no more than 2 lines of therapy.

4. Evidence of progression by RANO criteria based on MRI scan.

5. Residual lesion must be = 1.0 cm and < 5.5 cm contrast-enhancing in diameter as determined by MRI.

6. Age = 18 years.

7. Karnofsky Performance Score (KPS) = 70.

8. Life expectancy > 12 weeks.

9. Participants must have normal organ and marrow function.

10. Participants must commit to the use of a reliable method of birth control.

11. Resolution of all AEs due to previous therapies to = Grade 1 or baseline.

12. Capable of understanding and complying with protocol requirements.

Key Exclusion Criteria:

1. Inability to undergo MRI examination for any reason.

2. A contrast-enhancing brain tumor that does not meet protocol criteria.

3. Prior history of encephalitis, multiple sclerosis, or other CNS infection.

4. Clinical diagnosis of Li-Fraumeni Syndrome or with a known germ line deficit in the retinoblastoma gene or its related pathways.

5. Required steroid increase within 2 weeks prior to date of C5252 administration.

6. Systemic therapy with immunosuppressive agents within 28 days prior to date of C5252 administration.

7. Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or any other medical condition that precludes surgery. Also, psychiatric illness/social situations that would limit compliance with study requirements.

8. Bleeding diathesis, or requirement for anticoagulants, or antiplatelet agents, including NSAIDs that cannot be stopped for surgery or biopsy.

9. Current diagnosis of other cancer except in situ cervical cancer, basal or squamous cell carcinoma of the skin.

10. Requires continued concurrent therapy with any drug active against HSV (acyclovir, valaciclovir, penciclovir, famciclovir, ganciclovir, foscarnet, cidofovir).

11. Pregnant or lactating.

12. Prior organ transplantation.

13. Active hepatitis B virus, hepatitis C virus, or a positive serological test at Screening.

14. Active oral herpes lesion at Screening.

15. Congestive heart failure (> New York Heart Association Class II), active coronary artery disease, unevaluated new onset angina within 3 months or unstable angina (angina symptoms at rest), or clinically significant cardiac arrhythmias.

16. History of allergic reactions attributed to compounds of similar biological composition to HSV-1, IL-12, or anti-PD-1 monoclonal antibody.

17. Active infection with SARS-CoV-2 virus.

18. Other systemic conditions or organ abnormalities that, in the opinion of the Investigator, may interfere with the conduct and/or interpretation of the current study.

Related Conditions & MeSH terms

• Glioblastoma
• Glioblastoma Multiforme
• Glioblastoma Multiforme of Brain
• Solid Tumor

Intervention

Biological:
• C5252
A single dose of C5252 will be administered up to 2mL as intratumoral injection on Day 1.

Locations

Country	Name	City	State
United States	Huntsman Cancer Institute	Salt Lake City	Utah

Sponsors (1)

Lead Sponsor	Collaborator
ImmVira Pharma Co. Ltd

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Evaluate blood cytokines	Measure blood cytokines using MSD V-Plex Electrochemiluminescence Immunoassay test.	Up to 28 days from C5252 injection
Other	Evaluate lymphocyte profiling	Conduct lymphocyte profiling using PBMC Flow cytometry test.	Up to 28 days from C5252 injection
Primary	Evaluate the safety and tolerability of C5252	Number of participants in dose escalating cohorts with dose limiting toxicities (DLTs), treatment-emergent adverse events (TEAEs), and/or changes in clinical laboratory abnormalities.	Up to 28 days from C5252 injection
Primary	Characterize Dose Limiting Toxicities	Incidence of DLTs	Up to 28 days from C5252 injection
Primary	Identify the maximum tolerated dose (MTD) and/or the RD of C5252	Incidence of DLTs	Up to 28 days from C5252 injection
Secondary	Evaluate the PK of C5252	Measure anti-PD-1 antibody concentration in blood using Anti-PD-1 antibody ELISA test and IL-12 concentration in blood using IL-12p70 ELISA test.	Up to 2 years from C5252 injection
Secondary	Evaluate the viral shedding of C5252	Measure viral shedding of C5252 after intratumoral injection in saliva, nasopharyngeal mucus, and urine using qPCR (quantitative polymerase chain reaction) test.	Up to 2 years from C5252 injection
Secondary	Overall response rate (ORR)	ORR is defined as the proportion of participants who have had a partial response (PR), or complete response (CR) to intervention, based on Investigator Assessment for Neuro-oncology (RANO).	Up to 2 years from C5252 injection
Secondary	Progression-free survival (PFS)	PFS is defined as the time from Day 1 to the first documentation of progressive disease (PD) or death from any cause, whichever occurs first per RANO.	Up to 2 years from C5252 injection
Secondary	Overall Survival (OS)	OS is defined as the time from enrollment to death from any cause.	Up to 2 years from C5252 injection

External Links

•   ImmVira Pharma Co. LTD